Abstracts

GENERAL ABSTRACTS

General research abstracts will be accepted from August 30 through December 02, 2024, 11:59pm ET. 

Multiple research abstracts can be submitted by an individual. However, it is recommended to submit only one abstract per study. Submission of multiple abstracts on a single study may result in the rejection of one or more of the abstracts.

Abstract may be submitted in one of the below categories:

• Acute Kidney Injury/ICU Medicine
• Case Reports
• CKD/ESRD – Anemia
• CKD/ESRD - Cardiovascular Disease
• CKD/ESRD - Mineral Metabolism and Kidney Stones
• CKD/ESRD - Prevalence, Progression and Preparation for Dialysis
• CKD/ESRD - Vascular Access
• CKD/ESRD – Other
• Diabetic Nephropathy
• Electrolyte and Acid Base Abnormalities
• Glomerular Diseases
• Health Policy
• Hereditary Kidney Disease/PKD
• Home Dialysis - Home Hemodialysis/Peritoneal Dialysis
• Hypertension
• Interprofessional Collaboration
• Nutrition
• Transplantation
• Other

LATE-BREAKING ABSTRACTS

Late-breaking abstracts will be accepted from January 8 to February 1, 2025, 11:59pm ET. Only results from major clinical trials or epidemiological studies will be considered for review.

• Processing Fee: The $60 processing fee per abstract submission is nonrefundable. The fee must be paid at the time of submission by credit card.
• Character Limit: Each abstract is limited to a maximum of 2,500 characters including spaces, title, and author information. You may upload a figure in jpeg or png format which will reduce the maximum characters by 400 to 2100 characters. In addition, you may upload up to 3 supplementary files in pdf, jpeg, mp3 or mp4 format with a max size of 25 MB. Supplementary files will appear online only, they will not be published.
• Abbreviations & Subtitles: Use of standard abbreviations is desirable, e.g., RBC. Use kg., gm., mg., ml., L, and %. Place a special or unusual abbreviation in parentheses after the full word or phrase the first time it appears. Use numerals to indicate numbers, except to begin sentences. Do not use subtitles, e.g., Methods, Results.
• Case Reports: Please note that “Case Reports” is its own separate topic. Case Reports submitted should be novel and should have a single, well-defined message with meaningful clinical, diagnostic or therapeutic implications adequately supported by the clinical evaluation and diagnostic tests.
• Abstract Submission: The submitting author will be prompted to provide the following information:
  • Details: Select a topic, discipline, keywords, and 3 learning objectives.
  • Contributors: Submit the names, emails addresses, affiliations, and institutions for all authors involved. All contributors are responsible for submitting their own disclosures.
  • Introduction: Statement of the purpose of the study, program, project or case report.
  • Methods: Statement of the methods or interventions used.
  • Results: Summary of the results presented in sufficient detail to support the conclusion.
  • Conclusion: Statement of the implications, conclusions reached or key message.

• e-Posters & Onsite Information: Accepted abstracts may choose to display a poster in-person at the 2025 Spring Clinical Meetings in Boston, MA, upload an e-Poster to our virtual gallery, or both.
  • e-Posters: The submitting author will receive a notification once e-Poster submissions are being accepted in the SCM25 portal. 
  • Onsite Poster Q&A: All accepted abstract poster authors are invited to participate in the SCM25 Poster Author Q&A during the Opening Ceremonies on Thursday, April 10, from 5:15pm to 7:30pm ET. At this time, authors will stand near their poster to discuss with attendees and answer any questions. Those who choose to bring their poster to Boston, MA must register for the conference and print their poster themselves, as NKF does not offer printing services. 
  • Oral Abstract Sessions: Invitations for a select group of authors to formally present their research will be extended in January 2025. More details will be provided at a later date. The presentations will take place at SCM25 in Boston on Thursday, April 10, from 4:00pm to 5:00pm ET.

• Research and late-breaking abstracts must be electronically submitted through the NKF abstract submission site by their respective deadlines.
• NKF professional membership is not required for abstract submission, authorship, or presentation.
• Abstracts will not be considered if the research has been published and/or presented at another meeting or press conference prior to the Spring Clinical Meetings.
• The presenting author of an accepted abstract will have the option to bring a poster onsite for SCM25. However, acceptance of an abstract does not waive the registration fee. 
• Upon abstract submission, all contributors must agree to the NKF embargo policy.

In compliance with the Securities and Exchange Commission's Regulation FD (Fair Disclosure), accepted abstracts are made available to the public on the NKF website and are published in AJKD or JNSW (dependent on discipline) in advance of the meeting. Thus, the first release of the abstracts is a public release. Accepted abstracts are embargoed until the time of publication. Please note that abstract content published in AJKD or JNSW is copyrighted. Rights for reproduction or distribution must be requested through the respective journals. Poster content is not formally published within a journal and therefore the rights for reproduction or distribution remain with the author.

Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an abstract. However, the NKF continues to require that information that goes beyond that contained within the abstract, e.g., discussion of the abstract done as part of a scientific presentation, is to be embargoed until the start of SCM25, 8am ET on April 10, 2025. Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Journalists failing to abide by the embargo may have their press credentials revoked.

• Review: All abstract submissions are peer reviewed and determined as accepted or rejected.
• Publishing: NKF proudly publishes the majority of accepted abstracts as an electronic-only supplement in the April issue of the American Journal of Kidney Diseases (AJKD). Nephrology Social Work abstracts will publish in the spring issue of the Journal of Nephrology Social Work (JNSW). Edits to abstracts submitted via email to clinicalmeetings@kidney.org will be accepted until January 13, 2025. After this deadline, no further changes, including author updates, will be permitted. Accepted abstracts will be printed as they were submitted with any changes as of January 13, 2025.
  An example of the SCM2024 abstracts can be found here: https://www.ajkd.org/issue/S0272-6386(24)X0003-7

• General Research Deadlines: The general research abstract submission period opens on August 30, 2024 and must be submitted into the system by 11:59pm ET on December 02, 2024. 
• Late-Breaking Abstracts: The late-breaking abstract submission period opens on January 8, 2025, and closes on February 1, 2025, 11:59pm ET.
• SCM Registration: Registration for SCM25 opens in October 2024. The early-bird registration rate ends on February 7, 2025.
• SCM Attendance: Accepted abstracts may choose to display a poster in-person at the 2025 Spring Clinical Meetings in Boston, MA, upload an e-Poster to our virtual poster gallery, or both. Poster authors presenting in Boston, MA, are requested to attend the SCM25 Poster Author Q&A during the Opening Ceremonies on Thursday, April 10 from 5:15pm – 7:30pm ET.
• Notifications: NKF will email notifications to the submission author in early January 2025. The submitting author will receive all communication on behalf of the other contributors. It is the responsibility of the submitter to share the notification with the other contributors. 
• Abstract Edits: Edits to abstracts submitted via email to clinicalmeetings@kidney.org will be accepted until January 13, 2025. After this deadline, no further changes, including author updates, will be permitted. Accepted abstracts will be printed as they were submitted with any changes as of January 13, 2025.
• Withdrawals: The submitter may request abstract withdrawal through January 13, 2025, by emailing clinicalmeetings@kidney.org. After January 13, 2025, withdrawal requests will be accepted on a case-by-case basis, but the abstract may still be included in the e-supplement of AJKD. Please note, the $60 submission fee is nonrefundable.
• Oral Abstract Sessions: Invitations for a select group of authors to formally present their research will be extended in January 2025. More details will be provided at a later date. The presentations will take place on Thursday, April 10, from 4:00pm to 5:00pm ET.
• Disclosures: All contributors are responsible for submitting their own disclosures. Please allow adequate time to gather this information by May 25, 2025.